What are Non-depolarizing neuromuscular blocker drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-depolarizing neuromuscular blocker drugs are pharmacologic agents that share a common mechanism (typically targeting Nicotinic acetylcholine receptor). 0 are currently marketed, with 2 more in clinical development.

Non-depolarizing neuromuscular blocker

0 marketed 2 in Phase 3

This page covers all Non-depolarizing neuromuscular blocker drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nicotinic acetylcholine receptor.

Targets

Nicotinic acetylcholine receptor

Phase 3 pipeline (2)

rocuronium continuous infusion maintenance · Merck Sharp & Dohme LLC · Anesthesiology
Rocuronium acts as a competitive antagonist at the nicotinic acetylcholine receptor, preventing acetylcholine from binding and thereby inhibiting muscle contraction.
Rocuronium bolus maintenance · Merck Sharp & Dohme LLC · Anesthesiology
Rocuronium acts as a competitive antagonist at the nicotinic acetylcholine receptor, preventing acetylcholine from binding and thereby inhibiting muscle contraction.

Patent intelligence

non depolarizing neuromuscular blocker patent landscape — aggregated cliff calendar, attackable patents, originator estates